NASDAQ:IONS Ionis Pharmaceuticals (IONS) Stock Forecast, Price & News $46.26 -0.87 (-1.85%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$46.03▼$47.2050-Day Range$38.50▼$47.1352-Week Range$32.69▼$47.74Volume1.97 million shsAverage Volume1.05 million shsMarket Capitalization$6.63 billionP/E RatioN/ADividend YieldN/APrice Target$48.10 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ionis Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.44 Rating ScoreUpside/Downside4.0% Upside$48.10 Price TargetShort InterestBearish6.70% of Float Sold ShortDividend StrengthN/ASustainability-3.58Upright™ Environmental ScoreNews Sentiment0.71Based on 23 Articles This WeekInsider TradingSelling Shares$964,242 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.35) to ($3.56) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.18 out of 5 starsMedical Sector951st out of 969 stocksPharmaceutical Preparations Industry446th out of 455 stocks 1.2 Analyst's Opinion Consensus RatingIonis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 5 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $48.10, Ionis Pharmaceuticals has a forecasted upside of 4.0% from its current price of $46.26.Amount of Analyst CoverageIonis Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.70% of the float of Ionis Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverIonis Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Ionis Pharmaceuticals has recently increased by 0.97%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIonis Pharmaceuticals has received a 27.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication" product. See details.Environmental SustainabilityThe Environmental Impact score for Ionis Pharmaceuticals is -3.58. Previous Next 2.6 News and Social Media Coverage News SentimentIonis Pharmaceuticals has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Ionis Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest21 people have searched for IONS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $964,242.00 in company stock.Percentage Held by InsidersOnly 2.65% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions93.86% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to decrease in the coming year, from ($3.35) to ($3.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -21.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -21.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 11.48. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ionis Pharmaceuticals (NASDAQ:IONS) StockIonis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.Read More IONS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IONS Stock News HeadlinesSeptember 28, 2023 | finance.yahoo.comIonis (IONS) Inks New Deal With Roche to Develop Novel RNA DrugsSeptember 28, 2023 | finance.yahoo.comEplontersen Phase 3 results published in JAMA show consistent and sustained benefitSeptember 28, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 28, 2023 | americanbankingnews.comMorgan Stanley Increases Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $45.00September 27, 2023 | msn.comIonis' metabolic disorder drug lowers high levels of a type of fat in studySeptember 27, 2023 | finance.yahoo.comStrength Seen in Ionis Pharmaceuticals (IONS): Can Its 8.5% Jump Turn into More Strength?September 27, 2023 | finance.yahoo.comIonis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%September 27, 2023 | finance.yahoo.comIonis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's diseaseSeptember 28, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 26, 2023 | msn.comIonis Pharmaceuticals' Rare Metabolic Disorder Candidate Poised To Become New Standard Treatment, Study Shows Encouraging ActionSeptember 26, 2023 | msn.comIonis late-stage rare disease data fails to impress BernsteinSeptember 26, 2023 | finance.yahoo.comIonis Climbs On Late-Stage Trial Results For Body Fat DisorderSeptember 26, 2023 | reuters.comIonis Pharma's genetic disorder drug succeeds in late-stage studySeptember 26, 2023 | markets.businessinsider.comIonis Reports Positive Results From Phase 3 Study Of Olezarsen In Familial Chylomicronemia SyndromeSeptember 26, 2023 | reuters.comIonis Pharma's genetic disorder drug meets main goal in late-stage studySeptember 26, 2023 | finance.yahoo.comIonis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndromeSeptember 26, 2023 | finance.yahoo.comUPDATE 2-Ionis' metabolic disorder drug lowers high levels of a type of fat in studySeptember 21, 2023 | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Recommendation of "Hold" by AnalystsSeptember 21, 2023 | americanbankingnews.comLeerink Partnrs Comments on Ionis Pharmaceuticals, Inc.'s Q3 2023 Earnings (NASDAQ:IONS)September 20, 2023 | finance.yahoo.comIonis to host investor and analyst day eventSeptember 8, 2023 | finance.yahoo.comWhy Is Ionis Pharmaceuticals (IONS) Up 1.4% Since Last Earnings Report?August 11, 2023 | finance.yahoo.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2023 Earnings Call TranscriptAugust 10, 2023 | markets.businessinsider.comBarclays Remains a Hold on Ionis Pharmaceuticals (IONS)August 10, 2023 | msn.comIonis Pharmaceuticals (IONS) Reports Q2 Results: What Key Metrics Have to Say (Revised)August 10, 2023 | finance.yahoo.comQ2 2023 Ionis Pharmaceuticals Inc Earnings CallAugust 9, 2023 | finance.yahoo.comIonis reports second quarter 2023 financial resultsAugust 3, 2023 | seekingalpha.comNovartis and Ionis in pact for new cardiovascular therapySee More Headlines Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Company Calendar Last Earnings8/09/2023Today9/28/2023Next Earnings (Estimated)11/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IONS CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees796Year FoundedN/APrice Target and Rating Average Stock Price Forecast$48.10 High Stock Price Forecast$67.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+2.9%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-269,720,000.00 Net Margins-48.81% Pretax Margin-44.60% Return on Equity-59.17% Return on Assets-11.40% Debt Debt-to-Equity Ratio3.07 Current Ratio9.09 Quick Ratio9.00 Sales & Book Value Annual Sales$587 million Price / Sales11.42 Cash FlowN/A Price / Cash FlowN/A Book Value$4.03 per share Price / Book11.60Miscellaneous Outstanding Shares143,330,000Free Float139,528,000Market Cap$6.70 billion OptionableOptionable Beta0.51 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Brett P. Monia Ph.D. (Age 62)Founder, CEO & Director Comp: $1.71MMs. Elizabeth L. Hougen M.A. (Age 61)M.B.A., M.S., Exec. VP of Fin. & CFO Comp: $1.02MMs. Onaiza Cadoret-Manier M.A. (Age 58)M.B.A., M.S., Exec. VP, Chief Global Product Strategy & Operations Officer Comp: $930.82kMs. B. Lynne Parshall Esq. (Age 69)J.D., Sr. Strategic Advisor & Director Comp: $334.64kDr. Richard S. Geary Ph.D. (Age 65)Exec. VP & Chief Devel. Officer Comp: $946.26kMr. Joseph T. Baroldi M.A. (Age 44)M.B.A., M.S., Exec. VP & Chief Bus. Officer Comp: $815.87kMr. Darren GonzalesChief Accounting Officer & Sr. VPDr. C. Frank Bennett BSc (Age 66)Ph.D., Exec. VP & Chief Scientific Officer Mr. D. Wade Walke Ph.D.Sr. VP of Investor RelationsMr. Patrick R. O'Neil Esq. (Age 49)Exec. VP, Chief Legal Officer, Gen. Counsel & Corp. Sec. More ExecutivesKey CompetitorsAlkermesNASDAQ:ALKSImmunoGenNASDAQ:IMGNAmicus TherapeuticsNASDAQ:FOLDMadrigal PharmaceuticalsNASDAQ:MDGLUnited TherapeuticsNASDAQ:UTHRView All CompetitorsInsiders & InstitutionsVirginia Retirement Systems ET ALBought 34,600 shares on 8/22/2023Ownership: 0.024%Comerica BankBought 538 shares on 8/22/2023Ownership: 0.000%California State Teachers Retirement SystemSold 4,182 shares on 8/21/2023Ownership: 0.112%BOKF NASold 1,511 shares on 8/21/2023Ownership: 0.041%Osaic Holdings Inc.Sold 774 shares on 8/21/2023Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions IONS Stock - Frequently Asked Questions Should I buy or sell Ionis Pharmaceuticals stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares. View IONS analyst ratings or view top-rated stocks. What is Ionis Pharmaceuticals' stock price forecast for 2023? 9 equities research analysts have issued twelve-month target prices for Ionis Pharmaceuticals' shares. Their IONS share price forecasts range from $27.00 to $67.00. On average, they predict the company's share price to reach $48.10 in the next year. This suggests a possible upside of 2.9% from the stock's current price. View analysts price targets for IONS or view top-rated stocks among Wall Street analysts. How have IONS shares performed in 2023? Ionis Pharmaceuticals' stock was trading at $37.77 at the beginning of the year. Since then, IONS shares have increased by 23.8% and is now trading at $46.75. View the best growth stocks for 2023 here. When is Ionis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023. View our IONS earnings forecast. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced its quarterly earnings data on Wednesday, August, 9th. The company reported $0.60 earnings per share for the quarter, topping analysts' consensus estimates of ($0.94) by $1.54. The firm earned $188 million during the quarter, compared to analysts' expectations of $136.84 million. Ionis Pharmaceuticals had a negative net margin of 48.81% and a negative trailing twelve-month return on equity of 59.17%. What ETFs hold Ionis Pharmaceuticals' stock? ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Morningstar US Small Growth (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), Franklin Genomic Advancements ETF (HELX), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and VanEck Morningstar SMID Moat ETF (SMOT). What guidance has Ionis Pharmaceuticals issued on next quarter's earnings? Ionis Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $586.28 million. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD). What is Ionis Pharmaceuticals' stock symbol? Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS." Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Bellevue Group AG (6.54%), Clearbridge Investments LLC (3.62%), BVF Inc. IL (1.99%), Camber Capital Management LP (1.74%), ARK Investment Management LLC (1.69%) and Geode Capital Management LLC (1.51%). Insiders that own company stock include Allene M Diaz, B Lynne Parshall, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ionis Pharmaceuticals' stock price today? One share of IONS stock can currently be purchased for approximately $46.75. How much money does Ionis Pharmaceuticals make? Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $6.70 billion and generates $587 million in revenue each year. The company earns $-269,720,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis. How many employees does Ionis Pharmaceuticals have? The company employs 796 workers across the globe. How can I contact Ionis Pharmaceuticals? Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700. This page (NASDAQ:IONS) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.